You have reached the legacy site. Please visit our new site at

  The material posted on HIV and about AIDS 2010 is not approved by nor is it a part of AIDS 2010.
Library of Slides and Posters
HIV/AIDS Articles
HIV-HCV and HIV-HBV Coinfection Articles

    Google Custom Search

HIV/AIDS Articles
HPV-associated Cancer among HIV Positive Men and Women in the Combination ART Era
HIV Treatment Advances Have Not Decreased Mortality among Disadvantaged Groups in San Francisco
Long-term Non-progression of HIV Disease without Antiretroviral Treatment Is Uncommon
Switching from Efavirenz to Etravirine Reduces Central Nervous System Side Effects
Transmission of Drug-resistant HIV Increases Risk of Treatment Failure
Boosted Darunavir (Prezista) Monotherapy Provides Durable Viral Suppression for Most HIV Patients
People with HIV Develop Non-AIDS Cancers Earlier and More Often, despite Antiretroviral Therapy
Maraviroc (Selzentry) Not Associated with Elevated Cancer Risk in Clinical Development Program
CHARTER Study Finds Neurocognitive Impairment Still Common in ART Era, Linked to Lowest CD4 Cell Count
Half of Children Born to HIV Positive Mothers Do Not Receive Preventive Antiretroviral Drugs
Majority of HIV Positive People on Antiretroviral Therapy May Have Reduced Bone Density
Investigational HIV Drug TBR-652 Reduces Viral Replication and May Dampen Inflammation
Switching from Boosted Protease Inhibitor to Raltegravir Maintains Viral Suppression in Absence of NRTI Resistance
Early Antiretroviral Therapy during Tuberculosis Treatment Improves Survival
Oral Tenofovir for Pre-exposure Prophylaxis Appears Safe and Does Not Discourage Safer Sex
CASCADE Study Shows Antiretroviral Therapy Is Beneficial above CD4 Cell Count of 350, Less Clear above 500
New NNRTI Rilpivirine (TMC278) Shows Potent Antiviral Activity and Good Tolerability in Phase 3 Trials, FDA Application Submitted
Once-daily Extended Release Nevirapine (Viramune) Equals Twice-daily Immediate Release Formulation
Global Experts Call for Better Match between HIV Prevention Efforts and Groups at Greatest Risk
Experts Promote "Seek, Test, Treat and Retain" Paradigm and Opioid Substitution for Injection Drug Users
NRTI-sparing Regimen of Lopinavir/ritonavir plus Raltegravir Works as Well as Traditional 3-drug HAART
More Promising Data on GSK572 Integrase Inhibitor, Phase 3 Studies to Begin Soon
Early Antiretroviral Treatment Reduces New HIV Infections, Says British Columbia Study
New International AIDS Society-USA Guidelines Recommend Starting Antiretroviral Therapy at 500
CDC Study Reveals High HIV Infection Rates Linked to Poverty More than Race
IAPAC Survey Finds Gaps in Patient-Physician Conversations Affect Treatment Outcomes
AIDS 2010 Opens with Focus on Human Rights of People with HIV
Cure for HIV Is Feasible and Necessary, Experts Say
CAPRISA Microbicide Trial Shows Tenofovir Vaginal Gel Reduces HIV Transmission Risk by 39%
Histone Deacetylase Inhibitor Both Actives Latent CD4 Cells and Reduces Coreceptor Expression
Experts Call for "New Era" of Unified HIV Vaccine Research
ViiV Healthcare Extends Generic HIV Drug Licensing to More Low-income Countries
AIDS 2010 -- International AIDS Conference Begins Sunday in Vienna
Vienna Declaration Calls for Health-focused Drug Policy, International AIDS Conference Deadline July 13
HIV-HCV and HIV-HBV Coinfection Articles
HIV/HCV Coinfection, but Not HIV Alone, Raises Risk of Liver-related Death
Does Nevirapine Improve Response to Interferon-based Therapy in HIV/HCV Coinfected Patients?
HIV/HCV Coinfected People More Likely to Sustain Fractures Related to Bone Loss
People with HIV Have Higher Rate of Severe Liver Disease, Antiretroviral Therapy Cuts Risk
Library of Slides and Posters
Analysis of clinical outcomes in African American HIV-1 positive patients receiving lopinavir/ritonavir in a large urban AIDS clinic
P Kadlecik and others. AIDS 2010.
Limited future regimen options for those starting on NNRTI-based triple combinations due to antiretroviral drug resistance mutations
K Chan and others. AIDS 2010.
Clinical outcomes, immmunologic function and virologic suppression among HIV infected children receiving Lopinavir/ritonavir-based second line antiretroviral therapy at National Pediatric Hospital, Phnom Penh, Cambodia
S Sophan and others. AIDS 2010.
Comparison of total and unbound lopinavir (LPV) pharmacokinetics (PK) in HIV-infected pregnant women receiving lopinavir/ritonavir (LPV/r) soft-gel capsules (SGC) or tablets
G Taylor and others. AIDS 2010.
Single boosted protease inhibitor versus double boosted protease inhibitors for the salvage therapy in HIV-infected patients
W Manosuthi and others. AIDS 2010.
Antiretroviral monotherapy with ritonavir-boosted lopinavir or fosamprenavir in HIV-cirrhotic patients is a safe, effective and costs-saving strategy
A Moreno-Zamora and others. AIDS 2010.
Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment-naïve HIV-1 infected subjects
J Reynes and others. AIDS 2010.
Baseline HIV-1 RNA does not affect virologic response to lopinavir/ritonavir-based regimens in antiretroviral-naive subjects: results of a 96-week meta-analysis of >2400 subjects
J van Wyk and others. AIDS 2010
Market shift towards heat-stable lopinavir/ritonavir demonstrates the need for improved formulations for second line treatment of HIV/AIDS in low- and middle-income countries
B Waning and others. AIDS 2010.
The effect of lopinavir/r monotherapy on viral load and on the selection of resistance-associated mutations in seminal plasma
E Nunes and others. AIDS 2010.
Incidence of emtricitabine, tenofovir, raltegravir, and lopinavir resistance following twice-daily (BID) lopinavir/ritonavir (LPV/r) in combination with once-daily (QD) emtricitabine/tenofovir (FTC/TDF) or twice daily raltegravir (RAL) in antiretroviral-naïve, HIV-1 infected subjects: 48-week results of a 96-week randomized trial (study M10-336)
A Lawal and others. AIDS 2010.
The effect of lopinavir/ritonavir on the pharmacokinetics of TMC207, an investigational antimycobacterial agent
R van Heeswijk and others. AIDS 2010.
Real-life safety and efficacy of lopinavir/ritonavir (LPV/r) in drug-naive and antiretroviral (ARV) treatment-experienced HIV patients: 96-week follow-up
B Conway and others. AIDS 2010
Drug-resistant genotyping to guide selection of etravirine, darunavir and raltegravir in salvage therapy for multi-drug-resistant cases improves outcomes
N Miyazaki and others. AIDS 2010.
Duration of antiretroviral regimens including Raltegravir, Maraviroc, Darunavir and/or Etravirine in clinical practice
I Castillo and others. AIDS 2010.
Raltegravir and enfuvirtide as a "bridge" antiretroviral therapy in kidney-transplanted patients with HIV infection receiving everolimus and low-dose cyclosporine: a case-control study
S Cocchi and others. AIDS 2010.
Impact of raltegravir on immune reconstitution and thymopoiesis in HIV-1-infected patients with undetectable viremia on HAART
C Garrido and others. AIDS 2010.
Impact of the HIV-1 integrase flexibility on the alternative resistance pathways to raltegravir
S Abdel-Azeim and others. AIDS 2010.
Immunological benefit of raltegravir when used as part of switch strategies
C Garrido and others. AIDS 2010.
Early viral response in a cohort of heavily ARV-experienced patients receiving a salvage regimen recommended by a national advisory board in Mexico
Y Vargas-Infante and others. AIDS 2010.
Raltegravir-based-HAART and lymphoma chemotherapy
S Marcotte and others. AIDS 2010.
Virological response to atazanavir, ritonavir and tenofovir/emtricitabine: relation to individual pharmacokinetic parameters and adherence measured by medication events monitoring system (MEMS) in naïve HIV-infected patients (ANRS134 trial)
C Goujard and others. AIDS 2010.
METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two BOosted protease inhibitors on LIpids and other marKers): comparison of the metabolic effects of darunavir/ritonavir versus atazanavir/ritonavir over 12 weeks
J Aberg and others. AIDS 2010.
Long-term efficacy and safety of a switch to unboosted atazanavir (ATV) in well controlled HIV-1 infected patients, results of the NEAT Unboosted Atazanavir Cohort
A Rachline and others. AIDS 2010.
Safety and efficacy of treatment simplification to atazanavir/ritonavir plus lamivudine in patients on two NRTIs plus atazanavir/ritonavir with optimal virologic control: 24 weeks results from a pilot study (atazanavir and lamivudine simplification study, ATLAS)
A De Luca and others. AIDS 2010.
Risk of Neutropenia, anemia and skin-rash among HIV exposed infants receiving nevirapine and cotrimoxazole compared to cotrimoxazole prophylaxis alone
J Aizire and others. AIDS 2010.
Randomized trial comparing two nevirapine starting doses after switching from efavirenz due to side effects (the Venice/GESIDA-4905 study)
E Ribera and others. AIDS 2010.
Influence of CYP2B6 haplotype on plasma efavirenz and nevirapine levels when co-administered with rifampicin in HIV/TB co-infected Thai adults
S Uttayamakul and others. AIDS 2010.
Treatment outcomes of patients co-infected with HIV and tuberculosis who received nevirapine-based antiretroviral regimen: a 4-year prospective study
W Manosuthi and others. AIDS 2010
Comparison of 48 week efficacy and safety of 400 mg QD nevirapine extended release formulation (Viramune XR) versus 200 mg BID nevirapine immediate release formulation (Viramune IR) in combination with Truvada in antiretroviral (ARV) naïve HIV-1 infected patients (VERxVE)
J Gathe and others. AIDS 2010
Both Immune Activation and Viral Load are Reduced Within 28 Days by VS411, the First AntiViral-HyperActivation Limiting Therapeutic (AV-HALT). A Phase II Study
E Katabira and others. AIDS 2010.
DermaVir for initial treatment of HIV-infected subjects demonstrates preliminary safety, immunogenicity and HIV-RNA reduction versus placebo immunization
J Lunzen and others. AIDS 2010.
Pooled Week 48 efficacy and safety results from ECHO and THRIVE, two double-blind, randomised, Phase III trials comparing TMC278 versus efavirenz in treatment-naïve, HIV-1-infected patients
C Cohen and others. AIDS 2010.
Pharmacokinetic interaction study between TMC278, a next-generation NNRTI, and methadone
H Crauwels and others. AIDS 2010.
Relative bioavailability of a concept paediatric formulation of TMC278, an investigational NNRTI
H Crauwels and others. AIDS 2010.
Darunavir/ritonavir increases rosuvastatin concentrations but does not alter lipid lowering effect in healthy volunteers
C Fichtenbaum and others. AIDS 2010.
Hepatic laboratory parameters in the MONET Trial: association with Hepatitis C co-infection
M Nelson and others. AIDS 2010.
The MONET trial 96 week analysis: darunavir/r monotherapy versus darunavir/r + 2NRTIs, for patients with HIV RNA < 50 copies/mL at baseline
A Rieger and others. AIDS 2010.
Effect of adherence on virological response to once-daily versus twice-daily darunavir/ritonavir in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations: ODIN 48-week data
C Workman and others. AIDS 2010.
Effects of once-daily versus twice-daily darunavir/ritonavir on lipid parameters at Week 48 in treatment-experienced, HIV-1-infected patients with no darunavir resistance-associated mutations in the ODIN study
J Arribas and others. AIDS 2010.
Subgroup analysis and predictors of virological response in treatment-experienced, HIV-1-infected patients in the ODIN trial
P Cahn and others. AIDS 2010.
METABOLIK (Metabolic Evaluation in Treatment-naïves Assessing the impact of two Boosted protease inhibitors on LIpids and other marKers): Comparison of the Metabolic Effects of Darunavir/ritonavir versus Atazanavir/ritonavir over 12Weeks
J Aberg and others. AIDS 2010.
The SENSE Trial: Etravirine (ETR) shows fewer Neuropsychiatric Adverse Events than Efavirenz (EFV) in Treatment-naïve HIV-1 Infected Patients
B Gazzard and others. AIDS 2010.
Prevalence of genotypic and phenotypic susceptibility to etravirine in US samples received for routine resistance testing
G Picchio and others. AIDS 2010.
SWITCH-EE Study: A Randomized Cross-over Study to Compare Etravirine and Efavirenz treatment
A Nguyen and others. AIDS 2010.
Bioequivalence of the Co-Formulation of Emtricitabine/Rilpivirine/Tenofovir DF
A Mathias and others. AIDS 2010.
Switching from Kivexa [ABC/3TC ]+Kaletra [LPV/r] to Truvada [TDF/FTC]+Kaletra [LPV/r] Reduces High Cholesterol: Results of a 12 Week Randomized, Controlled Study (ROCKET II)
G Behrens and others. AIDS 2010.
Switching to Atripla® (EFV/FTC/TDF) from ABC/3TC FDC (Kivexa®/Epzicom®) + Efavirenz (EFV) Improves Lipid Levels Towards NCEP Recommendations: Primary Endpoint Results of a 24-week Randomised Study
G Moyle and others. AIDS 2010.
The SPARTAN Study: A Pilot Study to Assess the Safety and Efficacy of an Investigational NRTI- and RTV-Sparing Regimen of Atazanavir (ATV) Experimental Dose of 300mg BID plus Raltegravir (RAL) 400mg BID (ATV+RAL) in Treatment-Naïve HIV-Infected Subjects.
M Kozal and others. AIDS 2010.

AIDS 2010 News and Coverage AIDS 2010 News and Coverage
AIDS 2010 Coverage and News AIDS 2010 News and Coverage
AIDS 2010 Covera

ge and News AIDS 2010 News and Coverage
AIDS 2010 Coverage and News AIDS 2010 Coverage and News

























CROI 2010 Coverage